Immunovaccine Announces the Departure of Its Chief Financial Officer
HALIFAX, NOVA SCOTIA -- (MARKET WIRE) -- 06/07/10 -- Immunovaccine Inc. (TSX VENTURE: IMV), a vaccine development company, today announced the departure of its Chief Financial Officer, Mr. Gary Dodge, C.A. The Company has immediately initiated the search for his replacement.
"We wish Mr. Dodge every success in his future endeavours," said Dr. Randal Chase, president and CEO of Immunovaccine.
Immunovaccine Inc. (TSX VENTURE: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Immunovaccine Inc. Mr. Brian Lowe Vice President (902) 492-1819 [email protected] Immunovaccine Inc. Jennifer Ayotte Director Communications (902) 492-1819 [email protected] www.immunovaccine.com / www.imvaccine.com
Released June 7, 2010